Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2014 2
2015 2
2016 3
2017 4
2018 8
2019 9
2020 20
2021 25
2022 19
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: yan f. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: yan f. Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133. Clin Cancer Res. 2023. PMID: 36374555
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X, Vano YA, Su X, Helleux A, Lindner V, Mouawad R, Spano JP, Rouprêt M, Compérat E, Verkarre V, Sun CM, Bennamoun M, Lang H, Barthelemy P, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: yan f. Cell Rep Med. 2023 Nov 21;4(11):101287. doi: 10.1016/j.xcrm.2023.101287. Epub 2023 Nov 14. Cell Rep Med. 2023. PMID: 37967556 Free PMC article.
Metabolism-associated molecular classification of gastric adenocarcinoma.
Ye Y, Yang W, Ruan X, Xu L, Cheng W, Zhao M, Wang X, Chen X, Cai D, Li G, Wang Y, Yan F, Lu X, Jiang L. Ye Y, et al. Among authors: yan f. Front Oncol. 2022 Nov 16;12:1024985. doi: 10.3389/fonc.2022.1024985. eCollection 2022. Front Oncol. 2022. PMID: 36465405 Free PMC article.
110 results